Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 3/20 | 0.36 |
| ▸ | HTR2A | P28223 | 1/20 | 0.36 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.36 |
| ▸ | PGR | P06401 | 2/20 | 0.34 |
| ▸ | PPARG | P37231 | 3/20 | 0.33 |
| ▸ | BRD4 | O60885 | 1/20 | 0.32 |
| ▸ | BRD2 | P25440 | 1/20 | 0.32 |
| ▸ | BRD3 | Q15059 | 1/20 | 0.32 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.32 |
| ▸ | PTGDR2 | Q9Y5Y4 | 3/20 | 0.31 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.31 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5230404 | 0.84 | PGR (0.40) | PGR | |
| SCHEMBL4109666 | 0.83 | PGR (0.41) | PGR | |
| SCHEMBL5228213 | 0.82 | KDM4E (0.36) | KCNH2SLC6A4PGRPPARGPTGDR2 | |
| SCHEMBL4114683 | 0.82 | PGR (0.40) | PGR | |
| SCHEMBL5229393 | 0.82 | OPRL1 (0.34) | PGR | |
| SCHEMBL5224650 | 0.82 | PGR (0.39) | PGRBRD4BRD2BRD3CREBBP | |
| SCHEMBL5227964 | 0.81 | PTGDR2 (0.42) | PGRPTGDR2 | |
| SCHEMBL5228272 | 0.81 | PTGDR2 (0.36) | KCNH2HTR2ASLC6A4PGRPTGDR2 | |
| SCHEMBL5229047 | 0.80 | KCNH2 (0.36) | KCNH2PGRPTGDR2 | |
| SCHEMBL5224661 | 0.80 | P2RX7 (0.34) | HTR2APPARGPTGDR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-100408564-C | Pyrazole derivatives for treating HIV | PFIZER LTD (US) | 2008-08-06 | — | — | CN | claimed |
| EP-1377556-B1 | PYRAZOLE DERIVATIVES FOR TREATING HIV | PFIZER LTD (GB) | 2007-04-04 | — | — | EP | claimed |
| EP-1762567-A1 | Pyrazole derivatives for treating HIV | Pfizer Limited (GB) | 2007-03-14 | — | — | EP | claimed |
| CN-1514828-A | Pyrazole derivatives for treating HIV | — | 2004-07-21 | — | — | CN | claimed |
| EP-1377556-A1 | PYRAZOLE DERIVATIVES FOR TREATING HIV | Pfizer Limited (GB) | 2004-01-07 | — | — | EP | claimed |
| US-20030100554-A1 | Pyrazole derivatives | JONES LYN HOWARD (GB) | 2003-05-29 | — | — | US | claimed |
| WO-2002085860-A1 | PYRAZOLE DERIVATIVES FOR TREATING HIV | PFIZER LIMITED (GB) | 2002-10-31 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030100554-A1 | Pyrazole derivatives | REV1, SARS1, CYP2F1 | KCNH2 3503/4885HTR2A 4856/4885SLC6A4 4310/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.